« Return to News | Awards & Advancement

Pappas Ventures names Pat Gage to scientific advisory board

Monday, July 9, 2012 04:56 PM

Pappas Ventures, a life sciences investor based in Durham, N.C., has appointed L. Patrick Gage, PhD, to the company's scientific advisory board.

Gage has extensive experience in the biotech and pharmaceutical industry, overseeing the development of more than a dozen marketed biologics and vaccines, as well as several small molecule drugs. During his 18-year career at Hoffmann-La Roche, he held several leadership roles in research management, including service as vice president of exploratory research. Gage then joined Genetics Institute and ultimately served as president after Wyeth (now Pfizer) acquired the company. He was then named president of Wyeth Research, taking responsibility for global pharmaceutical and vaccine R&D, as well as global biopharmaceutical manufacturing.

Gage also founded enGage Biotech Consulting in 2003 to focus on guiding the development of new biopharmaceutical products and companies. In addition to his consulting work, he currently serves as chairman of Cytokinetics and chairman of Tetraphase Pharmaceuticals. He has previously served as chairman for PDL BioPharma and Adnexus Therapeutics.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.